JPMorgan Chase & Co. Has $110,000 Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

JPMorgan Chase & Co. boosted its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 58.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,770 shares of the company’s stock after buying an additional 3,612 shares during the quarter. JPMorgan Chase & Co.’s holdings in ClearPoint Neuro were worth $110,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC raised its stake in shares of ClearPoint Neuro by 562.6% in the second quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock valued at $915,000 after purchasing an additional 144,088 shares in the last quarter. Conway Capital Management Inc. bought a new stake in ClearPoint Neuro during the 3rd quarter worth approximately $1,586,000. Squarepoint Ops LLC bought a new stake in shares of ClearPoint Neuro during the second quarter worth $549,000. Cubist Systematic Strategies LLC acquired a new stake in ClearPoint Neuro in the 2nd quarter valued at about $419,000. Finally, Pekin Hardy Strauss Inc. acquired a new stake in shares of ClearPoint Neuro in the third quarter valued at approximately $541,000. 30.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CLPT. Lake Street Capital boosted their price target on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, January 21st. B. Riley lifted their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 28th.

ClearPoint Neuro Stock Performance

Shares of CLPT opened at $17.46 on Monday. The firm has a market cap of $481.55 million, a P/E ratio of -25.30 and a beta of 1.01. ClearPoint Neuro, Inc. has a 52 week low of $5.11 and a 52 week high of $19.00. The firm’s 50-day simple moving average is $15.25 and its 200 day simple moving average is $12.51.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Thursday, November 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The company had revenue of $8.12 million for the quarter, compared to the consensus estimate of $8.07 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. During the same quarter in the previous year, the company posted ($0.20) earnings per share. As a group, equities analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.